Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTC: LXRP) today announced its entry into a definitive
five-year agreement, via its subsidiary Lexaria Hemp Corp., to provide its
patented DehydraTECH(TM) technology to Universal Hemp LLC. Under the agreement,
Universal Hemp, a B2B manufacturer of high-performing hemp-derived bulk
ingredients to the consumer packaged goods and nutraceutical industries, will
utilize the technology in many CBD-based food ingredients to be produced and
sold across the U.S. immediately, as well as in Canada when regulations permit.
“We are very excited about signing this licensing agreement with Lexaria
Bioscience to bring to market Lexaria’s highly effective delivery system which
makes cannabidiol or hemp-derived CBD readily available in the human body,”
Universal Hemp CEO and Founder Chad Kahunahana said in the news release.
“Lexaria’s unique technology was developed over many years for specified
applications and is now, for the first time, being applied to CBD at scale and
available for general use. We anticipate our SuperBio Infusion line of
ingredients will become the industry leader for CBD-infused health and beauty,
food and beverage, wellness, athletic and other products where maximum
performance is vital. In terms of bioavailability, shelf stability and taste
this is the best performing technology in the market, hands down. Our corporate
customers cannot wait to put our water-soluble solution into their products!”
To view the full press release, visit http://ibn.fm/H5xd0
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented
delivery technology that promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. Lexaria has
multiple patents pending in over 40 countries around the world and has patents
granted in the USA and in Australia for utilization of its DehydraTECH(TM)
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
